Fuccella L M, Conti F, Corvi G, Mandelli V, Randelli M, Stefanelli G
Clin Pharmacol Ther. 1975 Mar;17(3):277-83. doi: 10.1002/cpt1975173277.
In a double-blind study, indoprofen was superior to placebo in decreasing pain in patients with primary and metastatic cancer and with neuralgia. A single oral dose of 200 mg was more active than a 100-mg dose. The preferences of patients proved to be a more sensitive parameter in this study than scores of pain intensity, pain relief, and other related measurements (SPID, TOTPAR, and Peak PID).
在一项双盲研究中，吲哚美辛在减轻原发性和转移性癌症患者以及神经痛患者的疼痛方面优于安慰剂。单次口服200毫克的剂量比100毫克的剂量活性更强。在本研究中，患者的偏好被证明是一个比疼痛强度评分、疼痛缓解及其他相关测量指标（SPID、TOTPAR和Peak PID）更敏感的参数。
